Stock Screener App

무료 -

설치하다

1.7107

16.67% 0.2407

C 4 Therapeutics Inc (CCCC)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - Yahoo Finance

C4 Therapeutics patents new B-Raf V600E mutant degradation inducers - BioWorld MedTech

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals

Nurix Therapeutics Grants $1.4M in Stock Options and RSUs to Attract Top Biotech Talent - Stock Titan

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - TradingView

Tenaya Therapeutics Awards Major Stock Options Package: 461K Shares for Strategic New Hires - Stock Titan

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

C4 Therapeutics Reports Q1 2025 Financial Results - TipRanks

C4 Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

C4 Therapeutics Inc (CCCC) Q1 2025 Earnings: EPS Loss of $0.37 Beats Estimate, Revenue Surges to $7.2 Million - GuruFocus

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

C4 Therapeutics Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eagle-Tribune

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

BDRX

$1.15

1.30%

ARGX

$584.68

0.75%

ALNY

$308.75

1.19%

ZLAB

$37.33

2.30%

ATHE

$4.68

3.35%

REGN

$492.00

1.78%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개